All GLG News Analyses Filed Under: Business of Medicine

Novartis, Sleeping Giant Wakes-Up in China

November 6, 2009

Analysis by:GLG Expert Contributor

Analysis of:  Novartis to invest US$ 1 bn to build largest pharma R&D institute in China | www.pharmabiz.com

Novartis to grow its China presence, late.Novartis has a slow response to market opportunities.GlaxoSmithKline and other big pharma players are perhaps too large to compete in the world's changing markets.

Ken PowellPresidentGenesis Business Development, LLC

FDA Publishes H1N1 Diagnostic Test Guidance

November 5, 2009

Analysis of:  FDA Publishes Guidance Document for H1N1 Dx | www.genomeweb.com

The FDA published document designed to help diagnostic test manufactures develop H1N1 tests and data that would accompany a FDA application to market them.  This follows on the recent issuance of CDC guidelines for H1N1 tests.

What Will Help The Poor?

November 3, 2009

Analysis by:GLG Expert Contributor

Analysis of:  Deficit Plays into Health Reform | www.washingtonpost.com

There is no doubt that a great deal of time, efforts and resources have gone into trying to find a solution to the healthcare problems and concerns that we deal with today. What is not as clear to those who really need these problems solved are the answers thus far. A lot of very smart people seemto...

Pharma Outsourcing: Where Will it End?

November 3, 2009

Analysis by:GLG Expert Contributor

Analysis of:  Quintiles inks pharma deals | www.outsourcing-pharma.com

A major supplier of clinical development services has just been awarded all of Astra Zeneca's clinical pharmacology work. Such work was traditionally performed internally but is now one of many stages of development being outsourced. This follows similar trends in research, where pharma companies are...

ASTRO/ACRO help win the fight against Reimbursement Cuts for Radiation Oncology

November 2, 2009

Analysis by:GLG Expert Contributor

Analysis of:  CMS announcement regarding Radiation Oncology Reimbursement for 2010 | cs.astro.org

Major news breaking.. CMS has decided to implement only a 1% cut annually for radiation oncology reimbursement.   This may be the most important news item in the world of oncology for the past decade.   Faced with untenable projected cut of 19%, CMS reversed course and reduced the reduction in paym...

It's Time for Health Care Reform--Not Just Health Insurance Reform!

October 30, 2009

Analysis by:GLG Expert Contributor

Analysis of:  The Health Care Reform Debate We Need | blog.nj.com

With so much emphasis on changing the health insurance system, the far greater need to change the delivery and financing of care has gotten relatively little mention, at least in the sound bites where most people receiving their daily news. We should not squander this once in a lifetime change for...

Shares That Go Bump In The Night

October 30, 2009

Analysis by:GLG Expert Contributor

Analysis of:  Transcept Pharma sleep drug denied approval, shrs sink | www.reuters.com

Transcept is developing Intermezzo for Middle of Night Insomnia. Intermezzo is low dose zolpidem (same chemical as Ambien). FDA's questions delay access to the $7 billion US sleep disorder market. Transcept's shares dropped dramatically on the news

HIV/AIDS DRUG-INDUS BIOTECH

October 27, 2009

Analysis by:GLG Expert Contributor

Analysis of:  Indus Biotech develops drug to control HIV/AIDS | www.pharmabiz.com

This is indeed great news for HIV sufferers all over the world. Since the drug is derived from botanical sources, the cost will be within the reach of millions in the developing world. It will also help those infected with HIV in the developed world where the cost of conventional therapies are extremely...

Turn around signs seen in healthcare !!! Dr. Reddy's & Ranbaxy beat the trend!!!

October 27, 2009

Analysis by:GLG Expert Contributor

Analysis of:  UPDATE 1-New generics help India Dr Reddy's beat Q2 f'cast | in.reuters.com

After 4 - 5 quaters of negative growth, cost cuts, product rationalization etc... we have some good news from bell weather stocks of Indian pharma market.Dr. Reddy's & Ranbaxy both are reporting profits after of year of dismal performance.This is also a sign of overall market changing its down ward...

a natural response by competitor

October 26, 2009

Analysis by:GLG Expert Contributor

Analysis of:  Boehringer Ingelheim receives approval from the European Commission for Mirapexin®/Sifrol® prolonged-release, once daily tablet for the treatment of Parkinson`s disease | www.pipelinereview.com

1. Requip XL will be coming out soon so BI had to come up with Mirapex once daily SR.2. Once daily dosing is probably better for our Parkinson's patients as this will provide continuous dopaminergic stimulation with less fluctuation.

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 1029